LEAP THERAPEUTICS, INC. — Director's Dealing 2017

Jan 24, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LEAP THERAPEUTICS, INC. (LPTX)
CIK: 0001509745
Period of Report: 2017-01-23

Reporting Person: Dietz Thomas John (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-01-23	Stock Option (Right to Buy)	$9.90	A	11000	Acquired	2027-01-22	Common Stock, $0.001 par value per share (11000)	Direct
2017-01-23	Stock Option (Right to Buy)	$9.90	A	15000	Acquired	2027-01-22	Common Stock, $0.001 par value per share (15000)	Direct

Footnotes

F1: The Option was granted pursuant to Leap's Amended and Restated 2012 Equity Incentive Plan and is fully vested as of the grant date.

F2: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 12 equal quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 23, 2017, the Vesting Start Date.